AboutContact usRSS
dotsbydots
SEARCHCONTACT US

Buzz

Most popular

Daily
Weekly
1
Oracle CEO: "If we continue on our current trajectory, reaching a valuation of a trillion dollars is inevitable"
2
Is your solitaire opponent actually a bot?
3
Once $5 billion IPO bound, Cybereason merges with Trustwave amid decline
4
Cloudera acquires Israeli startup Octopai to advance metadata and AI integration
5
Silverfort acquires Rezonate for several tens of millions to expand cloud security reach
More news

Drugs

20 stories about Drugs
עומרי שור מדיסייף

Medisafe Partners with American Healthcare Consulting Firm Lash

30.04.19|Meir Orbach
Lash will combine Medisafe's mobile drug compliance application into its current service programs, to help patients adhere to their drug-taking regimen
רפואה בריאות רפואי תרופות מחקר

Can-Fite BioPharma Receives $1 Million From CKD Pharmaceuticals as Part of Expanded Agreement

16.04.19|CTech
Israel-based Can-Fite expanded its distribution agreement with the South Korean company in February, and is entitled to up to $5 million more in milestones
מנכ"ל טבע קאר שולץ קור שולץ קר שולץ מנכ"ל טבע פברואר 2018

Market Indifferent to European Approval of Teva's Migraine Drug

02.04.19|Lilach Baumer
Teva's injection, one of three similar migraine drugs already approved in the U.S., is the third to receive European approval after Amgen Inc. and Novartis AG and Eli Lilly
קאר שולץ מנכל טבע

Teva’s Schultz is Running Out of Rope

14.02.19|Hezi Sternlicht
In the fourth quarter and annual earnings reported by the company Wednesday, Teva missed analyst consensus for non-GAAP earnings per share, and shareholders seem to be losing patience
מנכ"ל טבע החדש קור שולץ 2

CVS Picks Migraine Drugs by Teva, Eli Lilly, Snubs Amgen, Reuters Reports

27.01.19|Lilach Baumer
In October, American prescription benefits management company Express Scripts added Amgen and Eli Lilly’s drugs to its coverage but excluded Teva
נאסדק

Sustained Drug Release Company UroGen Aiming to Raise $150 Million on Nasdaq

24.01.19|Lilach Baumer
Goldman Sachs & Co. LLC, JP Morgan, and Jefferies are the joint bookrunners for the offering
בריאות דיגיטלית מדעי החיים רפואה טיפול 1

Pfizer Taps Israeli Machine Learning Drug Discovery Company CytoReason

10.01.19|Lilach Baumer
Under the agreement, CytoReason will receive payments "potentially equaling up to low double digit millions" of dollars
מנכ"ל טבע החדש קור שולץ 2

Copaxone Profit will Continue to Fall, But Teva is Set to Double Down on Biosimilars

08.01.19|Lilach Baumer and Hezi Sternlicht
Speaking at J.P. Morgan’s Healthcare Conference on Monday, CEO Kåre Schultz said he expects the U.S. generic market to stabilize in 2019
הפגנת עובדי טבע מול ביתה של גליה מאור

Teva Restructuring Cuts Deep into Israel’s Pharma Job Market, Exports

07.01.19|Amitay Gazit and Dror Reich
Israel's pharmaceutical export fell 21% in 2018, according to a new report. Teva let go around 1,200 Israeli employees last year
נאסדק

Drug Developer Entera Bio Down on Nasdaq Following Amgen Deal

12.12.18|Lilach Baumer
The deal, announced Tuesday, could see Entera receive up to $270 million in aggregate payments
מטה טבע פתח תקווה

Teva's Swiss Anti-Nausea Drug Patent Suit Reaches U.S. Supreme Court

05.12.18|Lilach Baumer
Teva was sued in 2011 by Swiss drug company Helsinn Healthcare over its intention to develop a generic version of Helsin's drug, which it released in the U.S. in March 2018
מוסף ניתוח מנתחים רופא רופאים חדר ניתוח

Biotech Company Polypid Raises $15 Million

07.11.18|Lilach Baumer
Israel-based Polypid develops encapsulating drug delivery technology that enables extended and localized release in the body
default image

Drug Developer Mapi Pharma Raises $10 Million from China's Jingxin Pharm

06.11.18|Lilach Baumer
The Xinchang, China-headquartered generic drugmaker is an existing investor, having made an initial $10 million investment in Mapi in 2016
מנכ"ל טבע החדש קור שולץ 1

U.S. Benefit Manager Express Scripts Snubs Teva Migraine Injection, Report Says

18.10.18|Lilach Baumer
A Wednesday Reuters report revealed the U.S. company will cover drugs by Eli Lilly and Amgen, but not by Teva
הפגנה מפגינים פיטורים טבע אשדוד

Teva Outsources Manufacturing in Anticipation of Israeli Plant Closure

27.08.18|Golan Hazani
The debt-laden drugmaker announced an aggressive reorganization plan in December, consisting of wide-spread asset divestments and layoffs, including in its home country of Israel
זיפים גילוח זקן

Perrigo to Collaborate with Acne Cream Company Sol-Gel on Generic Drug

16.08.18|CTech
Nasdaq-listed Sol-Gel is a clinical-stage company developing topical products for skin conditions
נאסד"ק וול סטריט

RedHill’s Clinical Trial Results Undermine Its Underwritten Offering

12.08.18|Dror Reich
The gastro treatment company announced a successful Crohn's disease treatment trial two weeks ago. While investors initially seemed hyped, successful trials from competitors brought RedHill’s stock down since
קאר שולץ מנכל טבע

Teva's American Dream Boat is Sinking

08.08.18|Uri Tal-Tene
Over the past six quarters Teva's North American sales have been in free fall. The company's operating profit is in even worse shape. Mylan's decision to slash the price tag on its generic Copaxone offering further threatens Teva's revenues, meaning the company must hurry to provide the three potential trump cards it has up its sleeve
מוסף רפואה מבחנה מבחנות תרופה תרופות בית חולים

China’s CMS Medical Signs Multi-Million Dollar Deal With Israeli Pharma Company Can-Fite

07.08.18|Amarelle Wenkert
New York-listed Can-Fite develops small molecule drugs used in the treatment of liver and inflammatory diseases and cancer
מעבדה רפואה 1 זירת הבריאות

Eli Lilly Signs Multi-Year Collaboration with Anima Biotech

23.07.18|Lilach Baumer
Israel-based Anima will receive an upfront payment of $30 million and $14 million for research, but could potentially get as much as $1.05 billion in milestones
Previous ArticlesMore Articles